Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Nature
Robichaux, Jacqulyne P JP; Le, Xiuning X; Vijayan, R S K RSK; Hicks, J Kevin JK; Heeke, Simon S; Elamin, Yasir Y YY; Lin, Heather Y HY; Udagawa, Hibiki H; Skoulidis, Ferdinandos F; Tran, Hai H; Varghese, Susan S; He, Junqin J; Zhang, Fahao F; Nilsson, Monique B MB; Hu, Lemei L; Poteete, Alissa A; Rinsurongkawong, Waree W; Zhang, Xiaoshan X; Ren, Chenghui C; Liu, Xiaoke X; Hong, Lingzhi L; Zhang, Jianjun J; Diao, Lixia L; Madison, Russell R; Schrock, Alexa B AB; Saam, Jennifer J; Raymond, Victoria V; Fang, Bingliang B; Wang, Jing J; Ha, Min Jin MJ; Cross, Jason B JB; Gray, Jhanelle E JE; Heymach, John V JV
Organotypic three-dimensional cancer cell cultures mirror drug responses in vivo: lessons learned from the inhibition of EGFR signaling.
Oncotarget
Jacobi, Nico N; Seeboeck, Rita R; Hofmann, Elisabeth E; Schweiger, Helmut H; Smolinska, Veronika V; Mohr, Thomas T; Boyer, Alexandra A; Sommergruber, Wolfgang W; Lechner, Peter P; Pichler-Huebschmann, Corina C; Önder, Kamil K; Hundsberger, Harald H; Wiesner, Christoph C; Eger, Andreas A
Discrepancies in cancer genomic sequencing highlight opportunities for driver mutation discovery.
Cancer Research
Hudson, Andrew M AM; Yates, Tim T; Li, Yaoyong Y; Trotter, Eleanor W EW; Fawdar, Shameem S; Chapman, Phil P; Lorigan, Paul P; Biankin, Andrew A; Miller, Crispin J CJ; Brognard, John J